Cover Image
Market Research Report

Global Cutaneous and Systemic Leishmaniasis Market - 2019-2026

Published by DataM Intelligence Product code 845194
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Cutaneous and Systemic Leishmaniasis Market - 2019-2026
Published: May 1, 2019 Content info: 130-180 Pages
Description

Global Cutaneous and Systemic Leishmaniasis Market Overview

The global cutaneous and systemic leishmaniasis market was worth the US $XX billion in 2018 and is forecasted to reach US $XX billion by 2026, at a CAGR of XX% during the forecast period.

Cutaneous leishmaniasis is also known as oriental sore, tropical sore, Aleppo boil, Delhi Boil or desert boil. It is the most common form of leishmaniasis affecting humans. The cutaneous form presents with skin ulcers. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sandfly. There are about twenty species of Leishmania that cause cutaneous leishmaniasis.

Global Cutaneous and Systemic Leishmaniasis Market - Market Dynamics

Research and development by prominent manufacturers of this market to introduce new drugs into the market, which are more effective as well as affordable is the key factor driving the global cutaneous and systemic leishmaniasis market. In addition, undergoing clinical trials, which are likely to receive regulatory approval along with increasing government spending on healthcare infrastructure is also estimated to boost the cutaneous & systemic leishmaniasis market. Rising prevalence of cutaneous & systemic leishmaniasis is expected to propel the market growth. According to WHO (World Health Organization), around 700,000 to 1 million new cases and some 26,000 to 65,000 deaths occur annually due to cutaneous and systemic leishmaniasis.

However, the treatment for cutaneous and systemic leishmaniasis is very expensive and can cause serious adverse effects such as vomiting, nausea, anorexia, myalgia, abdominal pain, headache, arthralgia, and lethargy and can rarely cause the severe reaction of fatal cardiac arrhythmia. Also, the WHO considers leishmaniasis as one of the main neglected diseases in the world. All these factors are hampering the global cutaneous and systemic leishmaniasis market growth.

Global Cutaneous and Systemic Leishmaniasis Market - Segment Analysis

Based on the indication the global Cutaneous and Systemic Leishmaniasis market is broadly segmented as cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis. Among all these visceral leishmaniases accounted for major market share in 2018, and is projected to grow at a high CAGR over the forecast period (2019-2026). Due to increasing incidences of visceral leishmaniasis. Visceral leishmaniasis (VL) is characterized by recurrent bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. According to WHO (World Health Organization), most cases occur in Brazil, East Africa and in South-East Asia, and approximately 50 000 to 90 000 new cases of VL occur worldwide every year.

Global Cutaneous and Systemic Leishmaniasis Market - Geographical Analysis

The global Cutaneous and Systemic Leishmaniasis market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. Latin America and the Asia Pacific accounted for major market share in 2018 and is projected to grow at a high CAGR over the forecast period. It is owing to the high incidence rate of cutaneous & systemic leishmaniasis, in these regions. With a high percentage of disease incidence annually, the demand for drug-based products is estimated to grow significantly. In 2018, globally, the annual rate of cutaneous leishmaniasis (CL) was estimated to be 0.7 to 1.2 million new cases per year. Approximately 75% of cutaneous leishmaniasis is majorly reported in Afghanistan, Algeria, Brazil, Colombia, Costa Rica, Ethiopia, Islamic Republic of Iran, North Sudan, Peru, and the Syrian Arab Republic. Brazil represents approximately 90% of the VL cases in the Latin America region.

Global Cutaneous and Systemic Leishmaniasis Market - Competitive Analysis

Significant players of the global cutaneous and systemic leishmaniasis market are GlaxoSmithKline Plc.; Gilead Sciences, Inc.; Profounda Pharmaceuticals; Knight Therapeutics Inc.; Janssen Global Services, LLC; Albert David Ltd; Jubilant Life Sciences Ltd; Novartis AG; Sanofi A.G; Bristol-Myers Squibb Company, and others. Majority of these prominent players are adopting few organic and inorganic strategies such as product launches, collaboration, and product agreements, and other key developments to enhance their product portfolio in the global cutaneous and systemic leishmaniasis market.

Why Purchase the Report?

  • Visualize the composition of the Cutaneous and Systemic Leishmaniasis market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the Cutaneous and Systemic Leishmaniasis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Cutaneous and Systemic Leishmaniasis market - level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1. Global Cutaneous And Systemic Leishmaniasis Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cutaneous And Systemic Leishmaniasis Market - Market Definition and Overview

3. Global Cutaneous And Systemic Leishmaniasis Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Indication
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Cutaneous And Systemic Leishmaniasis Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cutaneous And Systemic Leishmaniasis Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis

6. Global Cutaneous And Systemic Leishmaniasis Market - By Drug Class

    • 6.1.1. Introduction
    • 6.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 6.1.3. Market Attractiveness Index, By Drug Class
  • 6.2. Pentavalent Antimonials
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 6.3. Anti-fungal Drugs
  • 6.4. Antimicrobial / Anti-leishmanial

7. Global Cutaneous And Systemic Leishmaniasis Market - By Route of Administration

    • 7.1.1. Introduction
    • 7.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.3. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.3. Topical
  • 7.4. Injections

8. Global Cutaneous And Systemic Leishmaniasis Market - By Indication

    • 8.1.1. Introduction
    • 8.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.3. Market Attractiveness Index, By Indication
  • 8.2. Cutaneous leishmaniasis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. Mucosal leishmaniasis
  • 8.4. Visceral leishmaniasis

9. Global Cutaneous And Systemic Leishmaniasis Market - By Distribution Channel

    • 9.1.1. Introduction
    • 9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.3. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Global Cutaneous And Systemic Leishmaniasis Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. The U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. The U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East & Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

11. Global Cutaneous And Systemic Leishmaniasis Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Competitor Cutaneous And Systemic Leishmaniasis Strategy Analysis
  • 11.3. Comparative Product Portfolio Analysis
  • 11.4. Market Positioning/Share Analysis
  • 11.5. Mergers and Acquisitions Analysis

12. Global Cutaneous And Systemic Leishmaniasis Market - Company Profiles

  • 12.1. GlaxoSmithKline Plc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Gilead Sciences, Inc.
  • 12.3. Profounda Pharmaceuticals
  • 12.4. Knight Therapeutics Inc.
  • 12.5. Janssen Global Services, LLC
  • 12.6. Albert David Ltd
  • 12.7. Jubilant Life Sciences Ltd
  • 12.8. Novartis AG
  • 12.9. Sanofi A.G
  • 12.10. Bristol-Myers Squibb Company

13. Global Cutaneous And Systemic Leishmaniasis Market - Premium Insights

14. Global Cutaneous And Systemic Leishmaniasis Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
Back to Top